Xeplion (paliperidone)
- Region
- 🇪🇺 EU
- Active substance
- paliperidone
- Company
- Janssen-Cilag International
- Status
- Authorised
- Therapeutic area
- Schizophrenia
- EU approval
- Fri 04 Mar 2011
- Application
- EMEA/H/C/002105
- ATC
- N05AX13
- Official record
- www.ema.europa.eu
Indication
Xeplion is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Byannli (previously Paliperidone Janssen-Cilag International) Authorised ·
- 🇪🇺 Invega Authorised · Janssen-Cilag International NV
- 🇪🇺 Trevicta (previously Paliperidone Janssen) Authorised · Janssen-Cilag International NV
- 🇪🇺 Niapelf Authorised · Neuraxpharm Pharmaceuticals S.L.
Follow Xeplion
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.